A Phase I, Two-part, Open-label, Non-randomised Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects

Trial Profile

A Phase I, Two-part, Open-label, Non-randomised Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Afabicin (Primary) ; Afabicin (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Debiopharm
  • Most Recent Events

    • 27 Jun 2017 Results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics.
    • 15 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 09 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top